Increased Risk of Breakthrough Infection among Cytomegalovirus Donor Positive/Recipient Negative Kidney Transplant Recipients Receiving Lower Dose Valganciclovir Prophylaxis

被引：0
|
作者：
Stevens, D. [1 ]
Trofe-Clark, J. [1 ,2 ]
Blumberg, E. [2 ]
Wilck, M. [2 ]
Weikert, B. [2 ]
Goral, S. [2 ]
Bleicher, M. [2 ]
Sawinski, D. [2 ]
Abt, P. [2 ]
Levine, M. [2 ]
Porrett, P. [2 ]
Bloom, R. [2 ]
机构：
[1] Hosp Univ Penn, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2013年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：321 / 321
页数：1
相关论文
共 50 条
  • [31] Examining valganciclovir prophylaxis duration among high-risk donor seropositive/recipient seronegative heart transplant recipients in a larger cohort
    Imlay, Hannah
    Dumitriu Carcoana, Allison O.
    Fisher, Cynthia E.
    Wong, Beatrice
    Rakita, Robert M.
    Fishbein, Daniel P.
    Limaye, Ajit P.
    TRANSPLANT INFECTIOUS DISEASE, 2021,
  • [32] Cytomegalovirus Antiviral Resistance Among Kidney Transplant Recipients in a Phase 3 Trial of Letermovir vs Valganciclovir Prophylaxis
    Strizki, Julie M.
    Diamond, Tracy L.
    Teal, Valerie L.
    Gilbert, Christopher L.
    Wang, Weiwen
    Stauffer, Nicole
    Haber, Barbara A.
    JOURNAL OF INFECTIOUS DISEASES, 2024, 230 (06): : e1287 - e1298
  • [33] The burden of cytomegalovirus infection remains high in high-risk kidney transplant recipients despite six-month valganciclovir prophylaxis
    Raiha, Juulia
    Ortiz, Fernanda
    Mannonen, Laura
    Loginov, Raisa
    Lempinen, Marko
    Lautenschlager, Irmeli
    Helantera, Ilkka
    TRANSPLANT INFECTIOUS DISEASE, 2021,
  • [34] Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial
    不详
    TRANSPLANTATION, 2023, 107 (12) : 2448 - 2448
  • [35] Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients A Randomized Clinical Trial
    Limaye, Ajit P.
    Budde, Klemens
    Humar, Atul
    Vincenti, Flavio
    Kuypers, Dirk R. J.
    Carroll, Robert P.
    Stauffer, Nicole
    Murata, Yoshihiko
    Strizki, Julie M.
    Teal, Valerie L.
    Gilbert, Christopher L.
    Haber, Barbara A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2023, 330 (01): : 33 - 42
  • [36] Impact of Valganciclovir Prophylaxis Dosing in High Risk Cytomegalovirus Kidney and Pancreas Transplant Recipients with Delayed Graft Function
    Gharabagi, A.
    Geyston, J.
    Agarwal, A.
    Rao, S.
    Doyle, A.
    Dann, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 607 - 607
  • [37] Prolonged Low-Dose Prophylaxis With Valganciclovir in Cytomegalovirus-Negative Recipients of Kidney Transplants From Cytomegalovirus-Positive Donors Allows Seroconversion and Prevents Cytomegalovirus Disease
    Halleck, F.
    Khadzhynov, D.
    Schrezenmeier, E.
    Lehner, L.
    Budde, K.
    Staeck, O.
    TRANSPLANTATION PROCEEDINGS, 2017, 49 (10) : 2280 - 2284
  • [38] Cytomegalovirus Infection Prophylaxis Using Lower Dose Valganciclovir in Cardiac Transplant Patients: A Retrospective Analysis of Efficacy and Safety
    Grayburn, Ryan
    Anigbogu, Michael
    Godden, Jon
    Cho, Chi
    Zwicke, Dianne
    Cheema, Omar
    Hastings, T. Edward
    Sulemanjee, Nasir
    JOURNAL OF CARDIAC FAILURE, 2013, 19 (08) : S57 - S57
  • [39] Cytomegalovirus-negative kidney transplant recipients are at an increased risk for malignancy after kidney transplantation
    Rozen-Zvi, Benaya
    Lichtenberg, Shelly
    Green, Hefziba
    Cohen, Ori
    Chagnac, Avry
    Mor, Eytan
    Rahamimov, Ruth
    CLINICAL TRANSPLANTATION, 2016, 30 (09) : 980 - 985
  • [40] Cytomegalovirus Infection among Pediatric Heart Transplant Recipients in the Current Era of Valganciclovir Prophylaxis: Impact on Post-Transplant Outcomes
    Das, B. B.
    Niu, J.
    Sue, P. K.
    Prusty, B. K.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2019, 38 (04): : S219 - S220
12345